Table 1.
Patient demographics and baseline characteristics
| HER2 positive (n = 59) | HER2 negative (n = 59) | p | |||
|---|---|---|---|---|---|
| Age (Years/Range) | 62 (35–91) | 66 (37–88) | n.s. | ||
| Women (n/percentage) | 11 (19%) | 11 (19%) | n.s. | ||
| Positive family history for oncological diseases (yes/percentage) | 13 (22%) | 14 (24%) | n.s. | ||
| Positive family history for gastrointestinal malignancies (yes/percentage) | 2 (3%) | 4 (7%) | n.s. | ||
| Second tumor disease (yes/percentage) | 12 (20%) | 5 (8%) | n.s. | ||
| Nicotin abusus (yes/percentage) | 23 (39%) | 21 (36%) | n.s. | ||
| Primary tumor side | n.s. | ||||
| Stomach (yes/percentage) | 8 (14%) | 6 (10%) | |||
| GEJ (yes/percentage) | 48 (81%) | 50 (85%) | |||
| Esophagus (yes/percentage) | 3 (5%) | 3 (5%) | |||
| Histology | n.s. | ||||
| Adenocarcinoma (yes/percentage) | 57 (97%) | 57 (97%) | |||
| SCC (yes/percentage) | 2 (3%) | 2 (3%) | |||
| WHO 2019 Classification | n.s. | ||||
| Tubulary | 26 (44%) | 19 (32%) | |||
| Papillary | 5 (8%) | 2 (3%) | |||
| Poorly cohesive - signet ring cell type | 1 (2%) | 5 (8%) | |||
| Poorly cohesive - non signet ring cell type | 4 (7%) | 13 (22%) | |||
| Mucinous | 0 | 4 (7%) | |||
| Mixed types | 21 (37%) | 13 (22%) | |||
| Squamous | 2 (3%) | 2 (3%) | |||
| Adenosquamous | 0 | 1 (2%) | |||
| Lauren Classification | 0.001 | ||||
| Diffuse (yes/percentage) | 5 (8%) | 27 (46%) | |||
| Intestinal (yes/percentage) | 42 (71%) | 17 (29%) | |||
| Mixed (yes/percentage) | 11 (19%) | 11 (19%) | |||
| Advanced disease (yes/percentage) | 20 (34%) | 20 (34%) | n.s. | ||
| Number of metastatic sites per patient (n/range) | 1 (1–3) | 1 (1–3) | n.s. | ||
| 1 | 13 (22%) | 9 (15%) | |||
| 2 | 5 (8%) | 5 (8%) | |||
| 3 | 2 (3%) | 1 (3%) | |||
| Metastatic sites | n.s. | ||||
| Liver (n/percentage) | 11 (19%) | 9 (15%) | |||
| Peritoneum (n/percentage) | 6 (10%) | 3 (5%) | |||
| Lymphnode (n/percentage) | 2 (3%) | 1 (2%) | |||
| Lung (n/percentage) | 6 (10%) | 3 (5%) | |||
| Bones (n/percentage) | 1 (2%) | 3 (5%) | |||
| Muscles (n/percentage) | 1 (2%) | 2 (3%) | |||
| Omentum (n/percentage) | 0 | 1 (2%) | |||
| Tumor tissue type | n.s. | ||||
| Biopsy (n/percentage) | 24 (41%) | 16 (27%) | |||
| Resection (n/percentage) | 35 (60%) | 43 (73%) | |||
| Tumor Grade | 0.006 | ||||
| I (n/percentage) | 0 | 2 (3%) | |||
| II (n/percentage) | 31 (53%) | 18 (31%) | |||
| III (n/percentage) | 19 (32%) | 36 (61%) | |||
| TNM Classification | |||||
| T | n.s. | ||||
| 1 (n/percentage) | 7 (12%) | 5 (8%) | |||
| 2 (n/percentage) | 6 (10%) | 8 (14%) | |||
| 3 (n/percentage) | 24 (41%) | 29 (49%) | |||
| 4 (n/percentage) | 0 | 1 (2%) | |||
| N | n.s. | ||||
| 0 (n/percentage) | 14 (24%) | 7 (12%) | |||
| 1 (n/percentage) | 17 (29%) | 27 (46%) | |||
| 2 (n/percentage) | 7 (12%) | 9 (15%) | |||
| 3 (n/percentage) | 1 (2%) | 3 (5%) | |||
| L | n.s. | ||||
| 0 (n/percentage) | 9 (15%) | 3 (5%) | |||
| 1 (n/percentage) | 15 (25%) | 14 (24%) | |||
| V | 0.03 | ||||
| 0 (n/percentage) | 16 (27%) | 8 (14%) | |||
| 1 (n/percentage) | 6 (10%) | 12 (20%) | |||
| R | n.s. | ||||
| 0 (n/percentage) | 23 (40%) | 19 (32%) | |||
| 1 (n/percentage) | 4 (7%) | 4 (7%) | |||
| Gastrectomy (yes/percentage) | |||||
| Palliative (yes/percentage) | 9 (45%) | 3 (15%) | n.s. | ||
| Curative | 37 (95%) | 39 (100%) | n.s. | ||
n, number; HER2, human epidermal growth factor receptor 2; n.s., not significant; SCC, squamous cell carcinoma; WHO, World Health Organization; T, tumor stage; N, lymph node stage; L, lymphatic vessel invasion; V, vein invasion; R, resection boundary
Values are demonstrated in median, if not otherwise indicated